Drug intelligence / Profile preview

LYSP-15x

Development stage: Preclinical
Lead developer: Lysigen Biotechnology
Modality: Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

LYSP-15x is a recombinant lysin-based antimicrobial enzyme being developed by Lysigen for the treatment of blood stream infections. It is specifically designed to target and degrade the peptidoglycan layer of the bacterial cell walls of *Staphylococcus aureus* (including both methicillin-resistant [MRSA] and methicillin-susceptible [MSSA] strains) and various species within the *Streptococcus* genus. By cleaving the peptidoglycan, the enzyme causes rapid bacteriolysis. LYSP-15x is currently in the preclinical stage of development.

Targets

PGN (Peptidoglycan)

Beyond the preview

Go deeper on LYSP-15x.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LYSP-15x.

Explore the full profile